XML 30 R19.htm IDEA: XBRL DOCUMENT v3.25.3
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Service Fee Revenue
Our total revenues for the three and nine months ended September 30, 2025 and 2024 are presented in the table below. Our patient service revenue is displayed as the estimated service fee, broken down by classification of insurance coverage type, along with revenue generated from our management services and other sources such as software and AI.

In ThousandsThree Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Commercial insurance$287,769 $255,376 $829,295 $752,515 
Medicare123,254 102,853 347,641 298,001 
Medicaid13,470 10,894 37,735 32,804 
Workers' compensation/personal injury11,347 10,233 32,460 33,088 
Other payors29,962 25,366 87,064 77,336 
Management fee revenue7,044 6,241 20,011 18,255 
Other revenue18,580 16,616 44,632 35,514 
Revenue under capitation arrangements31,443 33,563 93,660 105,050 
Total service revenue$522,869 $461,142 $1,492,498 $1,352,563 
Schedule of Goodwill Activity in goodwill for the nine months ended September 30, 2025 is provided below (in thousands):
Imaging Center segmentDigital Health segmentTotal
Balance as of December 31, 2024628,537 $82,126 $710,663 
Goodwill from acquisitions61,306 47,084 108,391 
Measurement period and other adjustments— 87 87 
Currency translation1,741 6,650 8,391 
Balance as of September 30, 2025$691,584 $135,948 $827,532 
Schedule of Annual Amortization Expense The components of intangible assets, both finite and indefinite lived, along with annual amortization expense that will be recorded over the next five years at September 30, 2025 and December 31, 2024 are as follows (in thousands):
As of September 30, 2025:
2025*2026202720282029ThereafterTotalWeighted average amortization period remaining in years
Management service contracts$572 $2,287 $2,287 $2,287 $2,287 $4,384 $14,104 6.2
Covenant not to compete and other contracts258 787 493 403 234 45 2,220 3.2
Customer lists757 2,960 2,782 2,740 2,740 30,648 42,627 15.4
Patent and trademarks278 763 391 326 67 127 1,952 3.2
Developed technology2,438 9,714 9,180 9,180 3,952 8,982 43,446 5.2
Trade names amortized35 138 138 103 19 8 441 3.3
Others109 438 438 438 219 — 1,642 3.8
Trade names indefinite life— — — — — 8,500 8,500 
IPR&D— — — — — 9,980 9,980 
Total annual amortization$4,447 $17,087 $15,709 $15,477 $9,518 $62,674 $124,912 
*Excluding the nine months ended September 30, 2025

As of December 31, 2024:
20252026202720282029ThereafterTotalWeighted average amortization period remaining in years
Management service contracts$2,287 $2,287 $2,287 $2,287 $2,291 $4,384 $15,823 6.9
Covenant not to compete and other contracts947 660 365 275 106 — 2,353 3.2
Customer lists1,084 962 786 750 750 9,628 13,960 17.2
Patent and trademarks293 293 293 293 51 121 1,344 5.0
Developed technology7,329 7,289 6,755 6,755 1,848 4,610 34,586 5.4
Trade names amortized77 77 77 63 19 8 321 4.3
Trade names indefinite life— — — — — 8,500 8,500 
IPR&D— — — — — 4,464 4,464 
Total annual amortization$12,017 $11,568 $10,563 $10,423 $5,065 $31,715 $81,351 
Schedule of Foreign Currency Translation Amounts The following is a reconciliation of Foreign Currency Translation amounts for the three and nine months ended September 30, 2025 and 2024 is provided below (in thousands):
For the three months ended September 30, 2025
June 30, 2025 BalanceCurrency Translation Adjustments BalanceSeptember 30, 2025 Balance
Currency Translation Adjustments$7,935$(874)$7,061
For the nine months ended September 30, 2025
December 31, 2024 BalanceCurrency Translation Adjustments BalanceSeptember 30, 2025 Balance
Currency Translation Adjustments$(5,697)$12,758$7,061
Schedule of Effect of Derivative Instruments on Comprehensive Income( Loss)
A tabular presentation of the effect of derivative instruments on our condensed consolidated statement of comprehensive income of the 2019 Swaps is as follows (amounts in thousands):

For the three months ended September 30, 2025
AccountJune 30, 2025 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*September 30, 2025 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(217)$—$217$—Equity
*Net of taxes of $0 for the three months ended September 30, 2025.
For the nine months ended September 30, 2025
AccountDecember 31, 2024 BalanceAmount of comprehensive loss recognized on derivative net of taxesAmount of loss reclassified out of accumulated OCI into income (prior period effective portion), net of taxes*September 30, 2025 BalanceLocation
Accumulated Other Comprehensive Loss, net of taxes$(2,273)$—$2,273$—Equity
*Net of taxes of $0.7 million for the nine months ended September 30, 2025.

A tabular presentation of the effect of the 2019 Swaps on our statement of operations is as follows (amounts in thousands):

For the three months ended September 30, 2025
Ineffective interest rate swapAmount recognized (current period ineffective portion)Location recognized in profit and loss (current period ineffective portion)Amount reclassified from accumulated OCI (prior period effective portion)Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts$2,371 Other income (expense)$217 Interest Expense

For the nine months ended September 30, 2025
Ineffective interest rate swapAmount recognized (current period ineffective portion)Location recognized in profit and loss (current period ineffective portion)Amount reclassified from accumulated OCI (prior period effective portion)Location reclassified from accumulated OCI into profit and loss (prior period effective portion)
Interest rate contracts$6,433 Other income (expense)$2,273 Interest Expense
Schedule of Business Acquisitions by Acquisition, Contingent Consideration
A tabular roll forward of contingent consideration is as follows (amounts in thousands):
For the three months ended September 30, 2025
EntityAccountJune 30, 2025 BalanceAdditionsSettlement of contingent considerationChange in valuation of contingent considerationSeptember 30, 2025 Balance
See-Mode Technologies Pte. Ltd.Accrued expenses $2,114 $— $— $— $2,114 
See-Mode Technologies Pte. Ltd.Other non-current liabilities$6,652 $— $— $— $6,652 
Kolb Radiology P.C.Accrued expenses— $3,100 $— $— $3,100 
Kolb Radiology P.C.Other non-current liabilities— $1,400 $— $— $1,400 
For the nine months ended September 30, 2025
EntityAccountJanuary 1, 2025 BalanceAdditionsSettlement of contingent considerationChange in valuation of contingent considerationSeptember 30, 2025 Balance
See-Mode Technologies Pte. Ltd.Accrued expenses — $2,114 $— $— $2,114 
See-Mode Technologies Pte. Ltd.Other non-current liabilities— $6,652 $— $— $6,652 
Kolb Radiology P.C.Accrued expenses— $3,100 $— $— $3,100 
Kolb Radiology P.C.Other non-current liabilities— $1,400 $— $— $1,400 
Schedule of Fair Value of Assets and Liabilities
The tables below summarize the estimated fair values of certain of our financial assets that are subject to fair value measurements, and the classification of these assets on our condensed consolidated balance sheets, as follows (in thousands):
 As of September 30, 2025
Level 1Level 2Level 3Total
Current assets    
2019 Swaps - Interest Rate Contracts$— $679 $— $679 
 As of December 31, 2024
Level 1Level 2Level 3Total
Current assets    
2019 Swaps - Interest Rate Contracts$— $7,112 $— $7,112 
The table below summarizes the estimated fair values of contingent consideration relating to our acquisition that are subject to fair value measurements and the classification of these liabilities on our condensed consolidated balance sheets, as follows (in thousands):
 As of September 30, 2025
Level 1Level 2Level 3Total
Accrued expenses and other non-current liabilities    
See-Mode Technologies
$— $— $8,766 $8,766 
Kolb Radiology P.C.$— $— $4,500 $4,500 
The table below summarizes the estimated fair value compared to the face value of our long-term debt as follows (in thousands):
 As of September 30, 2025
Level 1Level 2Level 3Total Fair ValueTotal Face Value
Barclays Term Loan and Truist Term Loan$— $1,090,121 $— $1,090,121 $1,090,121 
 As of December 31, 2024
Level 1Level 2Level 3Total Fair ValueTotal Face Value
Barclays Term Loan and Truist Term Loan$— $1,006,713 $— $1,006,713 $1,005,625 
Schedule of Earnings Per Share Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, as follows (in thousands except share and per share data):
 Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$5,417 $3,209 $(18,055)$(2,552)
BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period75,950,350 73,494,709 74,703,658 72,587,321 
Basic net income (loss) per share attributable to RadNet, Inc.'s common stockholders
$0.07 $0.04 $(0.24)$(0.04)
DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
Weighted average number of common shares outstanding during the period75,950,350 73,494,709 74,703,658 72,587,321 
Add non-vested restricted stock subject only to service vesting241,221 233,235 — — 
Add additional shares issuable upon exercise of stock options and contingently issuable shares1,196,906 1,437,491 — — 
Weighted average number of common shares used in calculating diluted net income per share77,388,477 75,165,435 74,703,658 72,587,321 
Net income (loss) attributable to RadNet, Inc's common stockholders for diluted share calculation
$5,417 $3,209 $(18,055)$(2,552)
Diluted net income (loss) income per share attributable to RadNet, Inc.'s common stockholders
$0.07 $0.04 $(0.24)$(0.04)
Stock options and non-vested restricted awards excluded from the computation of diluted per share amounts as their effect would be antidilutive:
Non-vested restricted stock subject to service vesting— — 929,203 685,104 
Shares issuable upon the exercise of stock options— — 860,442 831,647 
Schedule of Investment in Joint Ventures
The following table is a summary of our investment in joint ventures during the nine months ended September 30, 2025 (in thousands):
Balance as of December 31, 2024$104,057 
Equity in earnings in joint ventures10,522 
Distribution of earnings(5,932)
Equity contributions in existing joint ventures20,480 
Balance as of September 30, 2025$129,127 
Schedule of Joint Venture Investment and Financial Information
The following table is a summary of key balance sheet data for these joint ventures as of September 30, 2025 and December 31, 2024 and income statement data for the nine months ended September 30, 2025 and 2024 (in thousands):
Balance Sheet Data:September 30, 2025December 31, 2024
Current assets$73,433 $61,158 
Noncurrent assets230,879 232,750 
Current liabilities(9,972)(53,182)
Noncurrent liabilities(72,316)(70,241)
Total net assets$222,023 $170,485 
Income statement data for the nine months ended September 30,
20252024
Net revenue$211,003 $195,905 
Net income$22,628 $23,949